Market Overview - On July 31, major indices experienced a downward trend, with the Shanghai Composite Index falling by 1.18%, the Shenzhen Component Index down by 1.73%, and the ChiNext Index decreasing by 1.66% [1] - The market saw significant declines in sectors such as coal, steel, shipping, oil, chemical fiber, real estate, non-ferrous metals, securities, insurance, aquatic products, and lithium mining [1] - The total market turnover approached 2 trillion yuan, with over 4,200 stocks declining [1] Individual Stock Performance - Notably, *ST Guandao, which resumed trading, hit the daily limit up, achieving a "30cm" ceiling price after previously being suspended for investigation [1][3] - In the assisted reproduction sector, stocks like A-share Gongtong Pharmaceutical, Lidiman, and Anke Bio all reached their daily limit up, indicating strong market interest [6] Policy and Regulatory Developments - The Beijing Municipal Government issued measures to enhance reproductive health services, including optimizing maternal and child healthcare resources and improving assisted reproductive technology [8] - As of June 2025, 253 million people participated in maternity insurance, with cumulative expenditures reaching 438.3 billion yuan, and 31 provinces included assisted reproduction projects in medical insurance reimbursement [8] Economic Indicators - The U.S. Federal Reserve maintained the federal funds rate target range at 4.25% to 4.50% following a two-day monetary policy meeting [9] - In the first half of 2025, China's gold jewelry consumption decreased by 26%, while investment demand for gold bars and coins increased by 23.69%, indicating a shift in consumer behavior due to high gold prices [9]

Core Viewpoint - The Hong Kong stock market saw a collective surge in the pharmaceutical and biotechnology sector, with notable gains in companies like Li Auto and China Biologic Products [2][4][12]. Group 1: Market Performance - The Hang Seng Index closed at 24,498.95 points, down 0.08%, while the Hang Seng Tech Index rose by 0.56% to 5,448.85 points [2]. - The total market turnover was HKD 236.4 billion, a decrease from the previous trading day, with net inflows from southbound funds amounting to HKD 1.855 billion [2]. - Among the constituent stocks, 43 rose and 40 fell, with Li Auto leading the gains at 9.73% [4]. Group 2: Notable Stock Movements - Li Auto's stock price increased by 9.73%, closing at HKD 124.10, with a year-to-date increase of 32.09% [5][19]. - China Biologic Products rose by 5.90%, with a significant year-to-date increase of 114.68% [5]. - The pharmaceutical sector saw a strong performance, with the Wande Pharmaceutical and Biotechnology Index rising by 4.65% [15]. Group 3: Sector Analysis - The healthcare sector increased by 5.17%, while the materials and energy sectors experienced declines of 1% and 0.94%, respectively [6]. - The CAR-T index rose by 8.19%, and the unprofitable biotech index increased by 6.28%, indicating strong investor interest in these areas [9]. Group 4: Regulatory Developments - The National Healthcare Security Administration and the National Health Commission introduced measures to support the high-quality development of innovative drugs, which is expected to enhance the role of commercial insurance in the multi-level medical security system [17]. - This regulatory change is anticipated to positively impact the upstream supply chain, including research reagents and CXO industries, with expected performance improvements starting from mid-2025 [17]. Group 5: Company-Specific News - Li Auto announced the opening of pre-orders for its i8 model, leading to a stock price increase of nearly 10% [18][19]. - The expected price range for the i8 is between RMB 350,000 and RMB 400,000, with the official price to be announced on July 29 [22].